SGHT - Glaucoma Player Sight Sciences Stock Falls More Than 30%: Analyst Warns Of Lingering Concerns Over Coverage | Benzinga
Sight Sciences Inc (NASDAQ: SGHT) shares are trading lower after the company issued third-quarter total revenue guidance below estimates and cut full-year 2023 revenue guidance below estimates.
Sight Sciences lowered FY23 revenue guidance from $89 million-$94 million to $80 million-$82 million versus the $92.12 million estimate.
Q3 revenue is anticipated to be between $19 million and $20 million versus the $23.72 million estimate.
The management attributed the roughly 17% sequential sales decline to impacts from the proposed local coverage determinations (LCDs) on June 2 that classified other tissue-removal devices, ...